Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329259 | 0.87 | PRKDC (0.42) | JAK2JAK1TYK2JAK3GAA | |
| SCHEMBL13329694 | 0.84 | JAK2 (0.47) | HSP90AA1HSP90AB1JAK2JAK1TYK2 | |
| SCHEMBL13329255 | 0.80 | MAPT (0.49) | JAK2GSK3AGSK3BGAARAB9A | |
| SCHEMBL13329676 | 0.76 | JAK1 (0.47) | JAK2JAK1TYK2JAK3ADORA2A | |
| SCHEMBL13360836 | 0.74 | HEXA (0.40) | JAK2JAK1TYK2JAK3ADORA2A | |
| SCHEMBL7256504 | 0.71 | JAK2 (0.51) | HSP90AA1HSP90AB1JAK2JAK1TYK2 | |
| SCHEMBL13329343 | 0.71 | EPHA4 (0.62) | JAK2JAK1TYK2JAK3GAA | |
| SCHEMBL13329477 | 0.71 | EPHA4 (0.66) | JAK2JAK1TYK2JAK3GAA | |
| SCHEMBL13329403 | 0.71 | EPHA4 (0.45) | JAK2JAK1TYK2JAK3GAA | |
| SCHEMBL13329790 | 0.71 | ABL1 (0.39) | JAK1TYK2JAK3RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | HSP90AA1 3537/4885HSP90AB1 3293/4885JAK2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.